Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Leases (2016 - 2025)

Lineage Cell Therapeutics' Operating Leases history spans 12 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 18.46% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 18.46%, while the annual FY2025 figure was $1.5 million, 18.46% up from the prior year.
  • Operating Leases reached $1.5 million in Q4 2025 per LCTX's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.9 million in Q4 2022 to a low of $1.0 million in Q1 2025.
  • Average Operating Leases over 5 years is $1.9 million, with a median of $1.9 million recorded in 2021.
  • Peak YoY movement for Operating Leases: skyrocketed 57.92% in 2023, then plummeted 51.16% in 2025.
  • A 5-year view of Operating Leases shows it stood at $1.9 million in 2021, then surged by 47.35% to $2.9 million in 2022, then tumbled by 30.8% to $2.0 million in 2023, then tumbled by 34.56% to $1.3 million in 2024, then rose by 18.46% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Operating Leases are $1.5 million (Q4 2025), $1.5 million (Q3 2025), and $1.1 million (Q2 2025).